Regeneron is trying for a second time to get approval for its blood cancer treatment. If possible, could you include the names of some related medications in your explanation?
The FDA plans to decide by July 30, 2025, whether to grant quick approval for a drug called odronextamab, which treats a type of cancer known as relapsed or refractory follicular lymphoma. This decision could bring a new treatment option to patients who have not responded well to other medicines.